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Background. A monthly treatment course of dihydroartemisinin-piperaquine (DHA-PQ) effectively prevents malaria during 
pregnancy. However, a drug–drug interaction pharmacokinetic (PK) study found that pregnant human immunodeficiency virus 
(HIV)–infected women receiving efavirenz-based antiretroviral therapy (ART) had markedly reduced piperaquine (PQ) exposure. 
This suggests the need for alternative DHA-PQ chemoprevention regimens in this population.
Methods. Eighty-three HIV-infected pregnant women who received monthly DHA-PQ and efavirenz contributed longitudinal 
PK and corrected QT interval (QTc) (n = 25) data. Population PK and PK-QTc models for PQ were developed to consider the ben-
efits (protective PQ coverage) and risks (QTc prolongation) of alternative DHA-PQ chemoprevention regimens. Protective PQ cov-
erage was defined as maintaining a concentration >10 ng/mL for >95% of the chemoprevention period.
Results. PQ clearance was 4540 L/day. With monthly DHA-PQ (2880 mg PQ), <1% of women achieved defined protective PQ 
coverage. Weekly (960 mg PQ) or low-dose daily (320 or 160 mg PQ) regimens achieved protective PQ coverage for 34% and >96% 
of women, respectively. All regimens were safe, with ≤2% of women predicted to have ≥30 msec QTc increase.
Conclusions. For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve pro-
tection against parasitemia and reduce risk of toxicity compared to monthly dosing.
Clinical Trials Registration. NCT02282293.
Keywords. intermittent preventive treatment during pregnancy; dihydroartemisinin-piperaquine; HIV infection;  
drug–drug interaction.
 
An estimated 28 million pregnancies occurred in malaria-en-
demic regions of Africa in 2015, placing infants at risk for the 
complications of placental malaria, including intrauterine growth 
retardation, preterm birth, low birth weight, and mortality [1]. 
Human immunodeficiency virus (HIV) infection increases 
these risks of malaria during pregnancy compared with HIV-
uninfected women [2]. To prevent malaria during pregnancy in 
moderate- to high-transmission areas in Africa, the World Health 
Organization (WHO) recommends use of insecticide-treated 
bed nets and intermittent preventive treatment during pregnancy 
(IPTp) with at least 3 doses of sulfadoxine-pyrimethamine (SP) 
[3]. HIV-infected women receive malaria chemoprevention with 
daily trimethoprim-sulfamethoxazole (TMP-SMX), a related 
antifolate that is also used to prevent other opportunistic infec-
tions [3]. Coadministration of SP and TMP-SMX is not recom-
mended due to increased risk for drug toxicity.
Antifolate resistance is now widespread in Africa, threaten-
ing the efficacy of SP and TMP-SMX for malaria chemopre-
vention [4]. A recent placebo-controlled chemoprevention trial 
among Ugandan children found a protective efficacy of only 7% 
for SP and 28% for TMP-SMX [5]. The artemisinin-based com-
bination therapy dihydroartemisinin-piperaquine (DHA-PQ) 
is under active study as an agent for IPTp because DHA rap-
idly clears circulating parasites and piperaquine (PQ), which 
has a half-life of several weeks, provides prolonged protection 
after therapy. Two recent trials of HIV-uninfected pregnant 
women in Uganda and Kenya, where Plasmodium falciparum 
predominates, found that administering a treatment course of 
DHA-PQ every 4 weeks, beginning in the second trimester, 
was associated with decreased malaria during pregnancy and 
decreased placental malaria [6, 7]. Population pharmacokinetic 
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/pharmacodynamic (PK/PD) modeling, conducted as part of 
the Ugandan trial, estimated that venous PQ concentrations of 
>10.3 ng/mL and >13.9 ng/mL were associated with 95% and 
99% protection from parasitemia during pregnancy (Savic et al, 
unpublished data).
A similar clinical trial evaluated monthly DHA-PQ for IPTp 
among HIV-infected women receiving efavirenz (EFV)–based 
antiretroviral therapy (ART) and TMP-SMX prophylaxis in 
Tororo, Uganda. There was an unusually low malaria burden 
during the trial, coinciding with district-wide indoor residual 
spraying of insecticide (IRS), and DHA-PQ did not show ben-
efit [8]. However, an intensive pharmacokinetic (PK) analysis 
among 26 trial participants revealed that women receiving EFV-
based ART experienced a 38% reduction in PQ exposure as 
measured by the area under the curve to 21 days (AUC0-21d), as 
compared to pregnant women who did not take EFV [9]. These 
findings suggest that coadministration of monthly DHA-PQ 
IPTp and EFV-based ART would result in low protective effi-
cacy in the setting of high malaria transmission. Therefore, our 
goal was to identify alternative DHA-PQ regimens for HIV-
infected pregnant women receiving EFV-based ART that would 
be predicted to provide optimal protective efficacy and safety. 
Toward this goal, we used available PK data, which included 
monthly measurements throughout chemoprevention, paired 
corrected QT interval (QTc) measurements, and population 
PK/PD modeling and simulations to predict the impacts of dif-
ferent dosing regimens on plasma levels of PQ.
METHODS
Study Setting and Participants
The clinical trial that provided samples for our analyses was 
conducted in Tororo, Uganda, from December 2014 through 
October 2015. The region has a history of high malaria trans-
mission intensity, but a district-wide program of IRS was imple-
mented in December 2014, with a subsequent dramatic decrease 
in malaria burden [10, 11]. Eligible women were ≥16 years of 
age; infected with HIV type 1 (HIV-1); lived within 30 km of the 
study site; and had a pregnancy between 12 and 28 weeks’ gesta-
tion [8]. Written informed consent was obtained from all study 
participants. The study protocol was approved by the Makerere 
University School of Biomedical Sciences Research and Ethics 
Committee, the Uganda National Council for Science and 
Technology, and the University of California, San Francisco 
Committee on Human Research. The clinical trial registration 
number is NCT02282293.
Study Design and Randomization
All women were prescribed ART with standard dosing of EFV/
tenofovir/lamivudine and a once-daily dose of TMP-SMX 
(160  mg TMP/800  mg SMX). Study subjects were random-
ized to receive either a treatment course of DHA-PQ (360 mg 
DHA/2880 mg PQ-phosphate divided into 3 consecutive daily 
oral doses, Holley-Cotec Pharmaceuticals) every 4 weeks or pla-
cebo. Administration of the first dose of DHA-PQ was observed 
in clinic, and the following doses were taken at home. DHA-PQ 
chemoprevention was started at 16, 20, 24, or 28 weeks’ ges-
tational age and continued every 4 weeks through birth or 40 
weeks’ gestational age.
Clinical Procedures
At enrollment, study participants received a long-lasting insec-
ticide-treated bed net, underwent a physical examination, and 
had blood collected. All women participated in routine visits at 
4-week intervals and returned to the clinic for all of their med-
ical needs. At routine visits, participants underwent a capillary 
blood draw for blood smear, plasma sample, and dried blood 
spot collection. At select visits, venous samples were obtained 
for similar studies.
Pharmacokinetic Sampling
Intensive PK Data
Details of the intensive PK study have been reported [9]. In 
brief, 28 consenting women from the trial were enrolled into 
an intensive PK substudy prior to their 28-week study visit [9]. 
Venous samples were collected on the day of the third daily dose 
of DHA-PQ at gestational week 28, and included samples pre-
dose (0 hours) and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose. 
Capillary plasma samples were collected at 24 hours and at 4, 7, 
14, and 21 days postdose.
Sparse PK Data
A convenience sample of 82 women provided capillary 
plasma samples permitting trough PQ concentration mea-
surements at routine prenatal visits occurring every 4 weeks, 
starting 4 weeks after the first DHA-PQ administration. 
Capillary samples were obtained by fingerprick prior to ad-
ministration of DHA-PQ using SAFE-T-FILL ethylenedi-
aminetetraacetic acid–containing capillary blood collection 
tubes. Plasma was obtained by centrifugation of PK samples 
within 60 minutes of collection at 2000g for 10 minutes, 
and then stored at –80°C. PQ base concentrations were de-
termined using high-performance liquid chromatography–
tandem mass spectrometry, as previously described [12]. 
Modification and partial validation of the original method 
for PQ quantitation was performed, to cover a concentration 
range of 0.50–1000 ng/mL. The lower limit of quantification 
(LLOQ) was 0.50 ng/mL and the coefficient of variation was 
<10% for quality control samples [12].
Protective Piperaquine Concentration
Due to lower than anticipated malaria burden observed in the 
clinical trial, PQ pharmacodynamic (PD) endpoints could 
not be determined [8]. Therefore, protective PQ concentra-
tions used for this study were estimated based on a random-
ized placebo-controlled trial conducted before institution of 
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IRS in Tororo. This trial studied HIV-uninfected pregnant 
women who received DHA-PQ for IPTp [7]. A  simultane-
ous PK/PD model from the trial defined the relationship 
between PQ concentration and the probability of parasite-
mia measured by loop-mediated isothermal amplification 
(LAMP). Using a conservative measure at the upper bounds 
of uncertainty from the model, PQ concentrations >10.3 ng/
mL and >13.9  ng/mL provided 95% and 99% probability, 
respectively, of being parasitemia free during pregnancy 
(Savic et  al, unpublished data). For the analysis in the cur-
rent report, 10 ng/mL and 14 ng/mL were used as the protec-
tive PQ concentrations. The time above these protective PQ 
concentrations was used as the PD endpoint. Protective PQ 
coverage was defined as maintaining a PQ concentration of 
>10 ng/mL for 95% of the chemoprevention period (ie, from 
initiation of chemoprevention at 20 weeks’ gestation through 
delivery).
Unlike the earlier trial of HIV-uninfected pregnant women 
from which the protective PQ concentrations were determined, 
all participants in this trial received TMP-SMX daily as part of 
standard management of their HIV infections. To account for 
potential additive protection against malaria with the combina-
tion of TMP-SMX and DHA-PQ, a protective PQ concentration 
of 5 ng/mL was also tested.
Population PK/PD Modeling and Simulation
A nonlinear mixed effects approach was used for the PQ pop-
ulation PK model development. The first-order conditional es-
timation method was employed during the analysis. In the first 
step, a separate model for intensive venous samples was estab-
lished. A joint model was then developed including both venous 
and capillary samples. PQ concentrations below the LLOQ were 
excluded, as they represented a small proportion of the PK data 
(2.2% of specimens).
Different structural models, including 1-, 2-, and 3-com-
partment models, with first-order absorption and with/without 
lag time were considered to fit the PQ data. The individual 
PK parameters were assumed to be log-normally distributed, 
and residual error variance was described by the proportional 
model. The relationship between capillary and venous samples 
was modeled using a linear relationship with estimated slope 
and fixed intercept of 0. The model appropriateness was assessed 
by the likelihood ratio test, inspection of the diagnostic plots, 
and internal model validation techniques, including visual and 
numerical predictive checks.
The final population PK model of PQ was used for the sim-
ulation of new dosing scenarios. One hundred groups of 100 
subjects were simulated for each dosing regimen, and com-
parisons of the percentage of women who achieved protective 
PQ coverage were made using the mean values of the groups. 
Dosing strategies were selected to maximize protective effi-
cacy and safety. Simulated regimens included monthly dosing 
(2880  mg PQ-phosphate and 360  mg DHA divided into 3 
consecutive daily oral doses once per month), weekly dos-
ing (960 mg PQ-phosphate and 120 mg DHA every 7 days), 
and 2 daily dosing options (320 mg PQ-phosphate with 40 mg 
DHA daily and 160  mg PQ-phosphate with 20  mg DHA 
daily). The weekly and daily regimens were also simulated 
with a DHA-PQ loading dose at the start of chemopreven-
tion (1 DHA-PQ treatment course at gestational week 20, 
followed by the weekly regimen starting on day 7 or day 28 
of chemoprevention or daily regimens starting on day 4 of 
chemoprevention).
Time above the protective PQ concentration, protective PQ 
coverage, and peak PQ concentration during pregnancy were 
predicted based on the PK model. A comparison between the 
PQ PK profiles of HIV-infected and HIV-uninfected pregnant 
women was estimated using previously determined PK param-
eters and the model from HIV-uninfected women (Savic et al, 
unpublished data).
A linear model was developed to determine the relationship 
between PK and QTc using simultaneous PK-toxicity mod-
eling, with estimated baseline and slope as functions of drug 
concentration at the time of QTc measurement. Analyses were 
performed using NONMEM (version 7.3), Stata (version 14.2), 
and R (version 3.3.2) software.
RESULTS
Summary of Clinical Results
In the clinical trial, 200 pregnant women with HIV were ran-
domized to receive either malaria chemoprevention with 
DHA-PQ every 4 weeks or placebo [8]. Eighty-three women 
who received IPTp with DHA-PQ and EFV-based ART con-
tributed PK data (Table  1). There were no significant differ-
ences in enrollment characteristics (age, weight, gestational 
age, CD4 cell count, LAMP positivity) between the women 
who provided PK samples and those who did not. Women who 
were not receiving ART prior to enrollment began EFV-based 
ART at least 4 weeks prior to all PK studies. All participants 
were followed through delivery. There were no episodes of ma-
laria among participants included in this analysis, and parasite 
prevalence was 1.6% as detected by LAMP (Table 1). For the 
analyses described in this report, only participants from the 
DHA-PQ arm were included.
Population Pharmacokinetic Model
Raw PQ Data
There were 505 PQ concentrations available: 378 were from 28 
individuals enrolled in the intensive PK substudy at gestational 
week 28, and 127 were monthly trough concentrations from 82 
individuals (1–4 samples per subject) taken between 20 gesta-
tional weeks and delivery (Figure 1). Ten sparse PK specimens 
(9.2%) and 1 intensive specimen (0.2%) had concentrations 
below the LLOQ and were excluded from analysis. Among the 
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117 detectable PQ trough measurements, the median PQ con-
centration was 1.75 ng/mL (interquartile range, 1.16–2.93 ng/
mL [range, 0.58–8.08 ng/mL]; Figure 1A).
PK Model Estimations
The final PK parameter estimates based on the structural 
2-compartment model with lag time are presented in Table 2. 
Typical oral clearance (CL/F) of PQ in pregnant HIV-infected 
women receiving EFV was estimated to be 4540  L/day with 
interindividual variability of 26%. Correlation between venous 
and capillary concentrations revealed a linear relationship, with 
a venous/capillary ratio of 0.776. The visual predictive check, 
shown in Figure  1B, demonstrates good PK model predicta-
bility and ability of the model to accurately simulate anticipated 
variability in population.
Using the PQ population PK model, with monthly DHA-PQ, 
no study participants achieved protective PQ coverage, defined 
as maintaining a PQ concentration >10 ng/mL for >95% of the 
time on DHA-PQ. When the lower PQ concentration of 5 ng/
mL was evaluated, 3.6% of the study participants achieved pro-
tective PQ coverage. The median cumulative PQ AUC during 
pregnancy was 2848 ng × hour/mL (standard deviation, 1145 ng 
× hour/mL [range, 1014–8322 ng × hour/mL]).
Simulations
Achieving Adequate PQ Protection
The predicted time above the protective PQ concentrations is 
presented in Table  3 and visualized for each DHA-PQ regi-
men in Figure 2. Less than 1% of women receiving monthly 
DHA-PQ and less than a quarter of women receiving weekly 
DHA-PQ achieved protective PQ coverage (Table  3 and 
Figure  2). In contrast, daily dosing achieved significantly 
improved coverage compared to monthly (P < .001) or weekly 
regimens (P  <  .001); 96.0% of women receiving the lower 
tested dose and 99.9% of those receiving the higher tested dose 
achieved protective PQ coverage. Adding a loading dose at 
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Figure 1. A, Distribution of trough piperaquine (PQ) concentrations by gestational week. Dots show measured concentrations. Box plots represent the median and inter-
quartile range. Concentrations below the limit of quantification (BLQ) were excluded from the analysis. B, Visual predictive check of final pharmacokinetic model. Dots repre-
sent measured PQ concentrations, the solid line is the observed median, and the dashed lines are the 5th and 95th percentiles of the observed data. Shaded areas represent 
simulated 5th, 50th, and 95th percentiles with uncertainty. Model fit is adequate if shaded areas from simulated data encompass solid and dashed lines representing the 
observed data.
Table  1. Characteristics of Study Participants Receiving Monthly 
Dihydroartemisinin-Piperaquine
Characteristic (N = 83a) No. (%)
Age, y, mean (SD) 29.8 (7.0)
CD4 count, cells/µL, mean (SD) 525 (249)
Receiving ART at enrollmentb 67 (81)
Malaria incidence during study period,  
events per person-year
0
Parasitemia detected during study periodc 5/312 (1.6)
Placental malaria by histopathology 5/81 (6.1)
Gestational age at first DHA-PQ dose
 16 wk 19 (23)
 20 wk 25 (30)
 24 wk 20 (24)
 28 wk 19 (23)
No. of trough PQ capillary concentrations 127
 24 wk 42 (33)
 28 wk 1 (0.8)
 32 wk 69 (54)
 36 wk 1 (0.8)
 40 wk 14 (11)
No. of intensive PQ concentrations,  
(venous/capillary)
378 (246/132)
No. of PQ concentrations below the  
limit of quantitation (sparse/intensive)
11 (10/1)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; DHA-PQ, dihydroartemisinin-piperaquine; PQ, 
piperaquine; SD, standard deviation.
aTwenty-eight subjects contributed intensive and 82 subjects contributed sparse pharma-
cokinetic data. 
bEfavirenz started ≥4 weeks prior to pharmacokinetic measurements. 
cBy loop-mediated isothermal amplification from a dried blood spot.
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/217/6/964/4762345 by Belgrade U
niversity user on 30 July 2019
968 • JID 2018:217 (15 March) • Wallender et al
the initiation of chemoprevention significantly improved the 
percentage of women who achieved protective PQ coverage 
for weekly regimens (P < .001), but did not for daily regimens 
(Table 3).
Protective PQ coverage with monthly DHA-PQ was com-
pared between HIV-uninfected women and HIV-infected 
women (all receiving EFV) using the previously determined 
parameters (Savic et  al, unpublished data) (Figure  3). As 
expected, the percentage of women who achieved protective 
PQ coverage was predicted to be significantly lower for HIV-
infected women compared with HIV-uninfected women (0.4% 
vs 24.3%; P < .001).
Peak Piperaquine Concentration and QTc Analysis
Risk of drug toxicity is related primarily to peak drug concen-
trations. In the case of PQ, there is concern for cardiotoxic-
ity, with demonstrated prolongation of the QTc interval [13]. 
Twenty-five trial participants contributed intensive PQ PK 
data and had their QTc measured after their third daily dose of 
DHA-PQ. The PK model was used to predict the PQ concentra-
tion at the time of QTc determination. A linear model with the 
equation QTc = modeled baseline QTc + [PQ] × 0.777 / 10 000 
best described the association between PQ PK and QTc.
 Figure 4 summarizes the predicted peak PQ concentrations 
during pregnancy and QTc changes for each DHA-PQ regimen. 
Peak PQ concentrations were highest among regimens that 
included at least 1 monthly (2880 mg PQ over 3 days) DHA-PQ 
dose. The mean maximum PQ concentration with a monthly 
regimen was 250  ng/mL (95% confidence interval [CI], 238–
262  ng/mL), with a maximum concentration of 549  ng/mL. 
Daily regimens had the lowest predicted PQ peak concentra-
tions, with a mean of 53.3 ng/mL (95% CI, 51.1–55.7 ng/mL) 
Table 2. Estimated Piperaquine Pharmacokinetic Parametersa
Parameter
Value  
(Relative SE)
Interindividual Variability 
(Relative SE)
No. (subjects/observations) 83/494
Clearance, L/d 4540 (7%) 26% (13%)
Volume of central compartment, L 4310 (17%) 31% (38%)
Intercompartmental clearance, L/d 2280 (14%) …
Volume of peripheral compart-
ment, L
15 300 (11%) …
Rate constant of absorption, 1/d 29.3 (32%) 101% (14%)
Lag time, d 0.0381 (2%) …
Ratio, venous/capillary 0.776 (17%) …
Proportional error 46% (9%) …
Abbreviation: SE, standard error.
aDose administered as piperaquine phosphate and concentration measured as piperaquine 
base.
Table 3. Percentage of Women Predicted to Achieve Protective Piperaquine Coveragea and Expected Degree of Corrected QT Interval Prolongation With 
Proposed Dosing Regimens
Piperaquine Dose No. of DHA-PQ Tabletsb
Mean Time >10 ng/mL 
(95% CI)c
Mean Percentage of Women Above the  
Protective PQ Target >95% of the Time, % (95% CI)c
Mean Percentage of 
Women With >30 msec 
Delta QTc, % (95% CI)d
5 ng/mL 10 ng/mL 14 ng/mL
2880 mg monthlye 9 tablets once  
monthly
38.0 (35.7–40.7.3) 5.4 (1.4–9.5) .4 (0–2.0) .1 (0–1.0) 1.8 (0–6.0)
960 mg weekly 3 tablets once  
weekly
64.8 (60.4–69.1) 76.5 (69.5–83.5) 24.0 (16.0–32.5) 7.2 (3.0–12.5) .8 (0–2.0)
160 mg daily Half-tablet daily 98.9 (98.0–99.6) 99.9 (99.0–100) 96.0 (92.0–99.0) 86.8 (80.0–93.0) 0
320 mg daily 1 tablet daily 99.9 (99.7–100) 100 (100–100) 99.9 (99.0–100) 99.4 (97.0–100) 0
2880 mg + 960 mg  
weekly beginning  
at 21 wk
9 tablets, then  
3 tablets weekly  
beginning at  
21 wk
69.7 (65.1–73.9) 80.7 (74.0–87.0) 33.6 (26.0–41.0) 14.6 (9.0–20.0) 1.4 (0–4.0)
2880 mg + 960 mg 
weekly beginning  
at 24 wk
9 tablets, then  
3 tablets weekly  
beginning at  
24 wk
59.5 (54.7–63.7) 18.6 (11.0–27.0) 1.6 (0–4.5) .3 (0–1.5) 1.7 (0–5.0)
2880 mg + 160 mg  
daily
9 tablets, then  
half-tablet daily
99.2 (99.1–99.9) 99.8 (99.5–100) 96.4 (92.5–99.0) 88.5 (82.5–95.0) 1.6 (0–4.0)
2880 mg + 320 mg  
daily
9 tablets, then  
1 tablet daily
99.9 (99.8–100) 100 (100–100) 99.8 (99.0–100) 99.4 (98.0–100) 1.4 (0–4.0)
Abbreviations: CI, confidence interval; DHA-PQ, dihydroartemisinin-piperaquine; PQ, piperaquine; QTc, corrected QT interval. 
aMaintaining the protective PQ concentration >95% of the time from gestational week 20 to delivery.
bRefers to adult tablets (40 mg dihydroartemisinin/320 mg PQ-phosphate). 
cAll differences within columns are statistically significant with P < .001 except for: mean time >10 ng/mL 160 mg daily vs 2880 mg + 160 mg daily (P = .91), 320 mg daily vs 2880 mg + 
160 mg daily (P = .09), 320 mg daily vs 2880 mg + 320 mg daily (P = 1.0), 2880 mg + 160 mg daily vs 2880 mg + 320 mg daily (P = .07); 5 ng/mL target, all regimens containing 160 mg daily 
or 320 mg daily had P = 1.0; 10 ng/mL target, 160 mg daily vs 2880 mg + 160 mg daily (P = .94), 320 mg daily vs 2880 mg + 320 mg daily (P = 1.0), 2880 mg monthly vs 2880 mg + 960 mg 
weekly at 24 weeks (P = .01); 14 ng/mL target, 2880 mg monthly vs 2880 mg + 960 mg weekly at 24 weeks (P = 1.0), 320 mg daily vs 2880 mg + 320 mg daily (P = 1.0).
dP < .001 for all comparisons between regimens containing 2880 mg vs those that did not, and when comparing 960 mg weekly vs either daily dose, otherwise P > .05. 
eFor monthly regimens, milligrams of PQ are divided into equal doses over 3 consecutive days.
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for 160 mg PQ daily, and 107 ng/mL (95% CI, 101–112 ng/mL) 
for 320 mg PQ daily. Greater than 30 msec of QTc prolongation 
at some point during the pregnancy was predicted for <2% of 
women taking at least 1 monthly dose of DHA-PQ (including 
a loading dose), for 0.8% of women receiving a weekly regimen 
without a loading dose, and for none of the women receiving 
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Figure 2. Results of simulations. A, Predicted piperaquine (PQ) concentrations from different dihydroartemisinin-piperaquine (DHA-PQ) chemoprevention regimens. All 
simulations assumed chemoprevention started at 20 weeks and continued through delivery (40 weeks). The horizontal dashed line represents 10 ng/mL, which has been 
associated with 95% protection from parasitemia during pregnancy. The blue dotted line indicates a PQ concentration of 5 ng/mL. B, Percentage of women receiving the 
indicated regimens of DHA-PQ who achieve protective PQ coverage by gestational week. Protective PQ coverage is defined as maintaining a PQ concentration of >10 ng/mL 
or >5 ng/mL for 95% of the time starting at gestational week 20.
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daily regimens. Indeed, the model predicted that none of the 
women receiving a 160 mg daily DHA-PQ regimen would expe-
rience >10 msec QTc prolongation.
Peak PQ concentrations with monthly DHA-PQ were pre-
dicted to be significantly higher for HIV-infected women com-
pared with HIV-uninfected women (mean, 250 vs 190 ng/mL; 
P < .001).
DISCUSSION
IPTp with DHA-PQ has great promise to reduce the burden of 
malaria during pregnancy in African women, but its benefits 
may be lost in HIV-infected women receiving EFV-based ART 
due to EFV-mediated cytochrome P450 (CYP) 3A4 induction, 
which leads to increased PQ clearance and reduced plasma 
exposure [9]. Considering other drugs received by study partic-
ipants, tenofovir, lamivudine, and TMP-SMX are not known to 
change CYP3A4 or CYP2C19 activity, making them less likely 
to contribute to these findings [14–16].
Less than 1% of women who received EFV and monthly 
DHA-PQ were predicted to achieve defined ideal protective PQ 
coverage. Although the protective efficacy of monthly DHA-PQ 
among trial participants could not be quantified in the setting 
of low malaria burden, the PQ PK model strongly suggests that, 
in the presence of high malaria transmission intensity, monthly 
DHA-PQ will not adequately prevent parasitemia. To identify 
regimens with improved PQ exposure, we simulated alternative 
DHA-PQ dosing schemes including weekly and daily schedules, 
with and without a treatment course of DHA-PQ at the begin-
ning of chemoprevention. Time above the protective PQ con-
centration increased with more frequent, lower-dose DHA-PQ 
administration, with daily DHA-PQ predicted to have the op-
timal protective PQ coverage and lowest risk of cardiotoxicity.
Prior to the institution of IRS in Tororo, HIV-infected women 
who received daily TMP-SMX experienced a high burden of 
malaria during pregnancy, and one-third had placental malaria 
[17]. Therefore, in settings of high malaria burden and antifo-
late resistance, HIV-infected women who take daily TMP-SMX 
will likely require an additional agent for effective malaria che-
moprevention. PQ models in nonpregnant adult males and 
Ugandan children have predicted that a weekly dose of 960 mg 
PQ should be considered to improve the protective efficacy of 
DHA-PQ [18, 19]. We also found improved PQ coverage with 
weekly regimens, with up to 34% of women predicted to achieve 
protective PQ coverage.
Daily low-dose DHA-PQ was estimated to provide protec-
tive PQ coverage for >98% of women. In addition to poten-
tially improved prevention of parasitemia, we suggest that 
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daily low-dose DHA-PQ chemoprevention during pregnancy 
for HIV-infected women receiving EFV-based ART may also 
minimize the risk of selection for drug resistance. We estimated 
that women receiving EFV-based ART and monthly DHA-PQ 
would spend an average of 62% of the chemoprevention period 
at risk for parasitemia with potentially detectable PQ concentra-
tions. Plasma PQ concentrations as low as 2.4 ng/mL have been 
associated with the selection for genetic markers of decreased 
susceptibility to antimalarials [20]. With daily DHA-PQ chemo-
prevention, <1% of women would be estimated to sustain PQ 
concentrations that permit parasitemia as detected by LAMP. 
Optimizing DHA-PQ dosing for chemoprevention could miti-
gate the potential risk for drug resistance.
High PQ concentrations have been associated with clinically 
significant QTc prolongation [13]. Efavirenz has also been 
associated with increases in QTc [21, 22]. In our analysis, QTc 
prolongation was linearly associated with PQ concentrations. 
Estimated peak PQ concentrations during pregnancy with 
monthly DHA-PQ were somewhat higher for HIV-infected 
women receiving EFV compared with those in HIV-uninfected 
women in the simulated data (Savic et al, unpublished data). 
This was an unanticipated finding, as EFV is not believed to 
affect PQ absorption. Sensitivity analysis suggested that the 
estimate of the absorption rate constant, which defines max-
imum concentration (Cmax), was highly influenced by data 
from 1 individual. Even with this high absorption constant 
and presence of EFV, none of the regimens resulted in Cmax 
values predicted to cause clinically significant QTc prolonga-
tion. Most importantly, modeling of low-dose daily DHA-PQ 
predicted minimal risk of QTc prolongation with excellent 
protective PQ coverage compared with monthly DHA-PQ 
with or without EFV.
Our study had some limitations. First, due to the unexpect-
edly low burden of malaria at the study site, insufficient power 
was available to assess PD endpoints. Second, the protective 
efficacy of daily TMP-SMX could not be determined. The pro-
tective efficacy of TMP-SMX during pregnancy is unknown, 
as it is standard of care for HIV-infected pregnant women. 
Considering other populations, among infants who received 
placebo or TMP-SMX in Uganda, the protective efficacy of 
TMP-SMX was 28%–49% [5, 23]. In a randomized trial, HIV-
infected adults who continued TMP-SMX experienced a pro-
tective efficacy of 70% against malaria compared with those 
who stopped the drug per WHO recommendations [24]. To 
explore the DHA-PQ dosing implications with the additive ben-
efit of TMP-SMX, we evaluated the time above a protective PQ 
concentration that was lowered by 50% (eg, 5 ng/mL) for each 
regimen. Even with this modified PQ concentration target, the 
daily DHA-PQ regimens remained optimal. Third, a biomarker 
that predicts the maximum benefit of IPTp is not available. 
We used the PD target of nearly eliminating LAMP positivity 
during pregnancy for >95% of women, as LAMP positivity has 
been associated with placental malaria, and to limit the poten-
tial selection of drug resistance [20, 25]. Fourth, daily or weekly 
DHA-PQ administration over a 6-month period during preg-
nancy has not been tested clinically, and side effects or impact 
on parasite determinants of drug resistance with this regimen 
have not been assessed.
Efavirenz-based ART is currently the WHO first-line treat-
ment for HIV during pregnancy [26]. We found that, for women 
receiving EFV-based ART in the absence of highly effective 
vector control measures such as IRS, low-dose daily DHA-PQ 
during pregnancy is likely to provide much greater protec-
tion against malaria than the monthly regimen that has been 
most studied. As future clinical trials are designed to evaluate 
the efficacy and safety of DHA-PQ chemoprevention for HIV-
infected women during pregnancy, daily low-dose DHA-PQ 
appears to be the most promising regimen for chemopreven-
tion. Our findings also support a potential benefit to switch-
ing to dolutegravir-based ART during pregnancy, which would 
avoid the drug–drug interaction responsible for decreased PQ 
concentrations with concurrent use of EFV [27]. Optimizing 
the dosing of DHA-PQ for chemoprevention in the setting of 
drug–drug interactions will be an important advancement in 
malaria control.
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